The UK- and India-based healthtech startup The Medical Travel Company (TMTC) has secured €3.8 million in funding to launch a comprehensive medical travel startup that connects UK patients with high-quality, affordable treatments in India. The investment round was led by Nexus Venture Partners, with additional participation from 4CAST, an athlete-led investment collective co-founded by England cricketers Ben Stokes and Jofra Archer, alongside Indian cricketer KL Rahul.
TMTC provides a full-stack solution for medical travel, enabling patients in the UK—particularly those facing long elective care wait times—to access world-class yet cost-effective treatment options in India. The platform ensures UK doctor involvement throughout the care journey, offers post-surgery insurance coverage, and manages end-to-end logistics, including travel, accommodation, aftercare, and recovery. The medical travel startup has witnessed consistent user growth and earned industry recognition for its role in advancing cross-border healthcare.
As of June 2025, an estimated 7.7 million people in the UK are waiting for elective procedures spanning orthopaedics, dental care, IVF, gynaecology, ophthalmology, and urology. With private treatment often prohibitively expensive, over 500,000 UK residents seek faster, more affordable care overseas each year. However, the global medical tourism market continues to face fragmentation, inconsistent quality, opaque pricing, and limited post-treatment support, all of which heighten patient uncertainty and risk.
Founded by Sahil Jain and Ankit Mehrotra, TMTC seeks to overcome these challenges through a clinician-led, structured model. UK doctors stay involved before, during, and after treatment, while patients receive care from internationally trained specialists at accredited hospitals in India. Additionally, each patient benefits from a 12-month post-surgery insurance policy that remains valid in the UK through a partner network of private hospitals. TMTC ensures a seamless experience by handling personalized aftercare and concierge-level travel logistics.
The company will deploy the new funds to expand clinical collaborations in the UK, build certified treatment pathways to enhance safety and transparency in medical travel, and develop digital infrastructure for maintaining comprehensive medical records—ensuring continuity of care once patients return home.
